# InteRNA Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/interna-technologies-b-v

- Industry: Pharmaceuticals
- Headquarters: Netherlands
- Website: www.interna-technologies.com
- Total disclosed funding: $33M
- Latest round: Series B (Feb 9, 2021)
- Investors on record: 5

## About

InteRNA Technologies B.V., based in the Netherlands, focuses on advancing RNA-based therapies for cancer treatment through innovative research and development initiatives.Founded in 2006 and headquartered in Nijmegen, Netherlands, InteRNA Technologies B.V. specializes in RNA-based therapeutic solutions. The company has conducted five deals with its most recent funding round being a GRANT of EUR 2.7 mn from the Netherlands Enterprise Agency on March 11, 2021. The total amount raised by the company to date is EUR 18.5 mn. Roel Schaapveld serves as the CEO and continues to lead its innovative endeavors.InteRNA Technologies B.V. is dedicated to developing RNA-based therapies targeting cancer treatment. The company emphasizes the advancement of clinical development projects with a focus on innovative and commercially viable products, processes, and services designed to meet unaddressed medical needs in oncology.InteRNA Technologies B.V. generates revenue through various funding rounds aimed at supporting its research and development activities. The company's revenue model is primarily dependent on securing grants, investments, and collaborations to finance its clinical trials and product development.With the recent GRANT funding of EUR 2.7 mn, InteRNA Technologies B.V. plans to accelerate its clinical development projects that exhibit strong commercial potential. The company is particularly focused on advancing new RNA-based therapies while exploring opportunities for expansion into additional markets and regions as clinical data becomes available. The grant will support the development of innovative products and processes, enhancing the company's position in the biopharmaceutical sector.

## Funding rounds

- Series B, Feb 9, 2021, $22M — Aglaia Oncology Funds, Oost NL, Alumni Ventures Group, Aurora Science
- Series A, Oct 29, 2015, $11M — Aglaia Oncology Funds, Inkef

## Investors

- Aglaia Oncology Funds (https://capitalatlas.ai/funds/aglaia-oncology-funds) — Series A, Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A
- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- Aurora Science (https://capitalatlas.ai/funds/aurora-science) — Series B